The Emphysema drugs in development market research report provides comprehensive information on the therapeutics under development for Emphysema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Emphysema. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Emphysema - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Emphysema and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Emphysema by 14 companies/universities/institutes. The top development phase for Emphysema is preclinical with nine drugs in that stage. The Emphysema pipeline has 11 drugs in development by companies and three by universities/ institutes. Some of the companies in the Emphysema pipeline products market are: Saban Research Institute of Childrens Hospital Los Angeles, S.Biomedics and University Hospital Freiburg.

The key targets in the Emphysema pipeline products market include Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1), Aminoacyl tRNA Synthase Complex Interacting Multifunctional Protein 1 (Multisynthase Complex Auxiliary Component p43 or AIMP1), and Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2).

The key mechanisms of action in the Emphysema pipeline product include Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1) Replacement with two drugs in Phase III. The Emphysema pipeline products include five routes of administration with the top ROA being Inhalational and six key molecule types in the Emphysema pipeline products market including Small Molecule, and Monoclonal Antibody.

Emphysema overview

Emphysema is a form of chronic obstructive pulmonary disease (COPD) that affects the air spaces distal to the terminal bronchiole, causing gradual damage to the tissue of the alveoli, reducing alveoli surface area and limiting the flow of oxygen. In emphysema, the walls between many of the air sacs in the lungs are damaged, which causes the air sacs to lose their shape and become floppy. This makes it harder for lungs to move oxygen in and carbon dioxide out of the body. Emphysema is diagnosed by pulmonary function testing (PFT), particularly spirometry, with chest x-ray used in severe cases. Management primarily attempts to dilate the alveoli, hence long-acting bronchodilators (LAB) and short-acting bronchodilators (SAB) are used alone or in combination with anti-inflammatory drugs, anticholinergics, or inhaled corticosteroids. Supportive therapy includes oxygen therapy, ventilatory support, palliative care, and pulmonary rehabilitation.

For a complete picture of Emphysema’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.